comprehensive -WSS

comprehensive

author：hotspot 2025-09-03 03:28:17 - browse：34748

Business standing in the middle of a maze near a bag with a dollar sign on it. -- biotech coverage from STAT — Adobe

Over the last year or two, something curious has started occurring in the conference rooms and private Zoom meetings of biotech venture capitalists.

Representatives from pension funds, college endowments, family offices, and other organizations with money to invest have become bolder in their requests, according to interviews with a host of VCs. They’re pushing not only for advantageous terms in a VC firm’s latest fund, but in some cases, have angled for equity in the firm itself. These types of conditions aren’t unheard of, but have become more frequent as venture capitalists have a harder time raising funds, and as outside investors feel empowered to ask for more bang for their buck.

“A lot is changing in venture fundraising right now,” said Nan Li, co-founder and managing partner of Dimension, which launched last January. Outside investors tried to ask for a piece of Dimension, but the new firm had more than enough interest in its first fund and was able to turn down those proposals. Two other young VC firms told STAT they’ve fielded similar requests, and one investment group reported that it had managed to negotiate an equity stake in a VC firm.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： 3 trends to watch in health tech's hiring outlook for 2024

hotspot

WSS

Why psychiatrists like me stop taking insurance

UCB departs biotech trade group BIO

IVG is promising — but it won’t replace IVF quite yet

How a scoliosis diagnosis changed the life of one young dancer

Some top drug companies are starting to take action on climate

CRISPR base editing slashes cholesterol levels in monkeys

Wikipedia

comprehensive

hotspot

What does generative AI mean for health care? We asked experts

Feng Zhang, Grail founder join forces on new gene editing startup

Trump demands the U.S. pay no more for drugs than other countries … again

Nobel honors Karikó and Weissman's enduring partnership

23andMe had bad news about my health. I wish a person had delivered it

RSV injection headlines need to be accurate for good uptake

DIEP, the 'gold standard' of breast reconstruction, is under threat

New weight loss drugs work. But how can they best be used?

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Ahead of JPM, here's who's profiting most in health care

knowledge

A single drug, study failures leave Anavex with nothing but cash

Antibiotic resistance and the global rise in human conflict

White House finalizes ITC's import ban of latest Apple Watches

The FDA must approve intranasal treatments for anaphylaxis

UCB departs biotech trade group BIO

2023 Nobel Prize in Medicine goes to Karikó and Weissman

hotspot

hotspot

Wikipedia

hotspot